483
Cordis CorporationFDA 483 - Cordis Corporation - January 12, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Cordis Corporation in Milpitas, CA, revealed a significant issue regarding the timely reporting of unanticipated adverse device effects (UADEs). The firm failed to submit reports of suprarenal stent fractures to all reviewing IRBs and participating investigators within the required 10 working days. This constitutes a deviation from their investigational plan and regulatory expectations for device safety reporting.
Open in Dashboard
ID · cd5e7d1c-e055-4312-ba9c-f694c946012e